Notice 16 Apr 2025 compliance, healthcare, regulation, controlled substances, oklahoma, drug enforcement administration, medical licensing

⚖️Revocation of Medical Registration

The Drug Enforcement Administration issued an Order to Show Cause for the revocation of Dr. Henry-Norbert O. Ndekwe's registration due to his lack of authority to handle controlled substances in Oklahoma. The document outlines the legal processes regarding the revocation and highlights the implications for healthcare practitioners and businesses in the industry.

Learn More
Rule 15 Apr 2025 healthcare, administrative practice and procedure, reporting and recordkeeping requirements, business compliance, medicare, penalties, health care, health facilities, health, medicaid, civil rights, privacy, health records, health insurance, individuals with disabilities, aged, grant programs-health, sex discrimination, citizenship and naturalization, prescription drugs, regulation changes, health maintenance organizations (hmo), religious discrimination, cost-sharing

💊Key Medicare and Medicaid Regulatory Changes for 2026

This final rule revises the Medicare Advantage (Part C), Medicare Prescription Drug Benefit (Part D), Medicare cost plan, and Programs of All-Inclusive Care for the Elderly (PACE) regulations to implement changes related to prescription drug coverage, the Medicare Prescription Payment Plan, dual eligible special needs plans (D-SNPs), Part C and D Star Ratings, and other programmatic areas, including the Medicare Drug Price Negotiation Program. This final rule also codifies existing sub-regulatory guidance in the Part C and Part D programs.

Learn More
Notice 11 Apr 2025 compliance, healthcare, regulations, privacy act, irs, social security

🏥SSA Announces New Matching Program with IRS for Medicare Benefits

In accordance with the provisions of the Privacy Act, as amended, this notice announces a new matching program with the United States Department of the Treasury, Internal Revenue Service (IRS). Under this matching program, the IRS will disclose IRS to SSA certain return information for the purpose of verifying eligibility for the Medicare Part D Low Income Subsidy (LIS) and determines the correct subsidy percentage of benefits provided under the Social Security Act (Act).

Learn More
Notice 11 Apr 2025 regulatory compliance, healthcare, grant opportunities, nih, research, infectious diseases

🧪NIH Notice of Closed Meeting for Grant Review in Health Sector

The Department of Health and Human Services announces a closed meeting by the National Institute of Allergy and Infectious Diseases to evaluate grant applications. The session, scheduled for May 2025, emphasizes confidentiality of discussions regarding trade secrets and personal information. This review is aimed at advancing research on anti-infective and immune disease therapeutics.

Learn More
Notice 11 Apr 2025 compliance, healthcare, business regulation, wage reporting, social security, low-income assistance

💼New Social Security Matching Program

In accordance with the provisions of the Privacy Act, as amended, this notice announces a new matching program with the United Stated Department of Health and Human Services, Office of Child Support Services (OCSS). Under this matching program, OCSS will provide SSA with quarterly wage (QW) and unemployment insurance (UI) information located in the National Directory of New Hires (NDNH) to allow SSA to determine eligibility of applicants for Extra Help (low-income subsidy assistance) under the Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003. This agreement assists SSA in determining eligibility of applicants for Extra Help, redetermining eligibility of existing Extra Help beneficiaries during periodic screening, and administering the Extra Help program.

Learn More
Notice 9 Apr 2025 public meeting, healthcare, nih, research, advisory council, policy discussion

🩺Notice of National Heart, Lung, and Blood Advisory Council Meeting

The Department of Health and Human Services announces a virtual meeting for the National Heart, Lung, and Blood Advisory Council. It aims to discuss program policies and issues that impact heart, lung, and blood health. The meeting is open to public attendance, with options for oral comments and presentations by interested individuals or organizations.

Learn More
Notice 9 Apr 2025 healthcare, pharmaceuticals, fda, drug approval, generic drugs, flumadine

💊FDA Confirms FLUMADINE Not Withdrawn for Safety or Effectiveness

The Food and Drug Administration (FDA, the Agency, or we) has determined that FLUMADINE (rimantadine hydrochloride) tablet, 100 milligrams (mg), was not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.

Learn More
Presidential Document 9 Apr 2025 healthcare, national events, social responsibility, public awareness, organ donation

❤️Proclamation for National Donate Life Month

This proclamation honors National Donate Life Month, recognizing the compassion of organ donors. It highlights the critical need for more registered donors and acknowledges the impact of donations on lives. The President urges Americans to consider signing up to be organ donors, emphasizing the life-saving potential of this selfless act.

Learn More
Notice 9 Apr 2025 healthcare, regulations, fda, pharmaceutical, drug approval, andas

💊FDA Finds VIBRAMYCIN Not Withdrawn, Impacts Generic Drug Market

The Food and Drug Administration (FDA, Agency, or we) has determined that VIBRAMYCIN (doxycycline) for oral suspension, equivalent (EQ) 25 milligrams (mg) base/5 milliliters (mL), was not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.

Learn More
Notice 9 Apr 2025 compliance, healthcare, pharmaceuticals, fda, drug regulations, market withdrawal

🚫FDA Withdraws Approval for 18 New Drug Applications

The Food and Drug Administration (FDA or Agency) is withdrawing approval of 18 new drug applications (NDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

Learn More